



BHRT Dosing Guidelines (Females)

PMS

Progesterone – Oral

- Ref #42: 300mg XR
½ tablet daily at bedtime on Days 1-10, then 1 tablet BID-QID on Day 11-until start of menstruation

Progesterone – Topical

- Ref #39: 30-40mg transdermal
- Ref #43: 20-40mg cream – Start using once a day on Day 12 until 2 weeks prior to period, and then BID-TID during week prior to period

Premenopausal

Bi-est – Topical

- Ref #42: (80:20) 0.375mg/mL plus progesterone cream 40mg/mL –Apply 1 mL to thin-skinned area daily at bedtime

Progesterone – Oral

- Ref #22,23: 200mg/day

Progesterone – Vaginal

- Ref #22: 400mg vaginal pessary/suppository
- Ref #23: 300-600mg/day over 2-3 doses
- Ref #23: 45-90mg/day sustained-release
- Ref #42: 30-40mg/mL – Apply 0.5mL to thin-skinned area on Days 1-10, and then 1mL QD on a different thin-skinned site Days 11-28

Testosterone – Oral

- Ref #42: 4mg in oil – Take 1 capsule QD

Testosterone – Topical

- Ref #30: 150 or 300mcg/day transdermal

Perimenopausal

DHEA – Oral

- Ref #34: 50mg/day

Postmenopausal

Estradiol - Oral

- Ref #1,4,5,6,7,8,41: 2mg/day micronized estradiol
- Ref #3,41: 1mg/day micronized estradiol on 1st-25th day of each month
- Ref #31: 50mg every 3 months
- Ref #36: 0.7-1.05mg/day
- Ref #38: 0.5mg/day

Estradiol – Topical

- Ref #2: 0.050mg/day continuous transdermal estradiol (surgical menopause)
- Ref #5: 1.5mg transdermal
- Ref #6: 1g transdermal gel
- Ref #7: 0.1mg twice weekly transdermal
- Ref #41,44: 0.5-2.5mg/day gel once a day in the morning on 1st-25th day of each month

Estradiol – Vaginal

- Ref #28: 0.125mg and 0.5mg daily

Estriol – Oral

- Ref #9,10,11,12,13,14,15,16,17,18: 2-8mg/day
- Ref #40: 0.5-5.0mg/day

Estriol – Vaginal

- Ref #19,44: 0.5mg vaginal cream once each night for 2 weeks
- Ref #42: 1mg vaginal suppository – Insert 1 suppository vaginally daily at bedtime for 3 days, then twice weekly at bedtime
- Ref #28: 0.5mg daily

Bi-est (80:20) or (90:10) – Oral

- Ref #40,41,42: 1.25, 2.5, 5.0mg on 1st-25th day of each month

Bi-est – Transdermal

- Ref #41: (50:50) 0.5-3mg/day in the morning on 1st-25th day of each month
- Ref #41: (80:20) 0.1-1.2mg/day in the morning on 1st-25th day of each month

Tri-est (80:10:10) – Oral

- Ref #40: 1.25, 2.5, 5.0mg
- Ref #41: 2-8mg/day in the morning on 1st-25th day of each month

Tri-est (80:10:10) – Vaginal

- Ref #41: 0.1-0.6mg/day at bedtime on 1st-25th day of each month

Progesterone – Oral

- Ref #20,36: 300mg/day at bedtime 10 days a month (for regular monthly bleeding)
- Ref #20,21,36: 200mg/day 14 days a month (to remain amenorrheic)
- Ref #20: 100mg/day 25 days a month (to remain amenorrheic)
- Ref #25: 100mg/day for 1st 23 days of each month
- Ref #26,41: 50-200mg/day micronized progesterone on 1st-25th day of each month
- Ref #27,42: 400mg/day micronized progesterone
- Ref #44: 100-200mg QD-BID for at least 2 weeks a month

Progesterone – Topical

- Ref #24,40,42: 20mg/day cream – Apply 20mg to thin-skinned area daily at bedtime
- Ref #43,44: 20-40mg cream QD-BID on Days 12-26 to thin-skinned area
- Ref #38: 100mg micronized progesterone vaginally
- Ref #41: 100-400mg/day on 1st-25th day of each month
- Ref #44: ¼ - ½ tsp of 2% progesterone cream

Progesterone – Vaginal

- Ref #28: 25mg and 50mg daily

Testosterone – Topical

- Ref #29,37: 150 or 300mcg/day transdermal
- Ref #31: 50mg implants every 3 months
- Ref #41: 2.5-10mg/day liposomal gel

Testosterone – Vaginal

- Ref #44: 1-2mg natural testosterone in a cream base 2-3 times a week
- Ref #28: 0.25mg and 0.5mg daily

DHEA – Oral

- Ref #33: 25-50mg/day
- Ref #35: 100mg/day
- Ref #41,44: 5-30mg/day

DHEA – Topical

- Ref #32,41: 10% cream (3-6g) once daily in the morning

DHEA - Vaginal

- Ref #28: 1.25mg and 50mg daily

Pregnenolone – Oral

- Ref #44: 25-200mg QD

REFERENCES:

- 1.) Carson PR, Elkind-Hirsch KE, Buster JE, et al. Effect of postmenopausal estrogen replacement on circulating androgens. *Obstet Gynecol.* 1997 Dec;90(6):995-8.
- 2.) Basbug M, Aygen E, Tayyar M, et al. Twenty two weeks of transdermal estradiol increases sex hormone-binding globulin in surgical menopausal women. *Eur J Obstet Gynecol Reprod Biol.* 1997 Jun;73(2):149-52.
- 3.) Slater CC, Zhang C, Hodis HN, et al. Comparison of estrogen and androgen levels after oral estrogen replacement therapy. *J Reprod Med.* 2001 Dec;46(12):1052-6.
- 4.) Snabes MC, Payne JP, Kopelen HA, et al. Physiologic estradiol replacement therapy and cardiac structure and function in normal postmenopausal women: a randomized, double-blind, placebo-controlled, crossover trial. *Obstet Gynec.* 1997 Mar;89(3):332-9.
- 5.) Chen FP, Lee N, Soong YK, et al. Comparison of transdermal and oral estrogen-progestin replacement therapy: effects on cardiovascular risk factors. *Menopause.* 2001 Sept-Oct;8(5):347-52.
- 6.) Karjalainen A, Heikkinen J, Savolainen MJ, et al. Metabolic changes induced by peroral oestrogen and transdermal oestrogen gel therapy. *Br J Obstet Gynaecol.* 1997 Nov;104 Suppl 16:38-43.
- 7.) Walsh BW, Li H, Sacks FM. Effects of postmenopausal hormone replacement with oral and transdermal estrogen on high density lipoprotein metabolism. *J Lipid Res.* 1994 Nov;35(11):2083-93.
- 8.) Haines C, Chung T, Chang A, et al. Effect of oral estradiol on Lp(a) and other lipoproteins in postmenopausal women. A randomized, double-blind, placebo-controlled, crossover study. *Arch Intern Med.* 1996 Apr 22;156(8):866-72.
- 9.) Head KA. Estriol: safety and efficacy. *Altern Med Rev.* 1998 Apr;3(2):101-13.
- 10.) Tzingounis VA, Aksu MF, Greenblatt RB. Estriol in the management of the menopause. *JAMA.* 1978 Apr 21;239(16):1638-41.
- 11.) Yang TS, Tsan SH, Chang SP, et al. Efficacy and safety of estriol replacement therapy for climacteric women. *Zhonghua Yi Xue Zhi (Taipei).* 1995 May;55(5):386-91.
- 12.) Takahashi K, Okada M, Ozaki T, et al. Safety and efficacy of oestriol for symptoms of natural and surgically induced menopause. *Hum Reprod.* 2000 May;15(5):1028-36.
- 13.) Nozaki M, Hashimoto K, Inoue Y, et al. Usefulness of estriol for the treatment of bone loss in postmenopausal women. *Nippon Sanka Fujink Gakkai Zasshi.* 1996 Feb;48(2):83-8.
- 14.) Minaguchi H, Uemura T, Shirasu K, et al. Effect of estriol on bone loss in postmenopausal Japanese women: a multicenter prospective open study. *J Obstet Gynaecol Res.* 1996 Jun;22(3):259-65.
- 15.) Nishibe A, Morimoto S, Hirota K, et al. Effect of estriol and bone mineral density of lumbar vertebrae in elderly and postmenopausal women. *Nippon Ronen Igakkai Zasshi.* 1996 May;33(5):353-9.
- 16.) Hayashi T, Ito I, Kano H, et al. Estriol (E3) replacement improves endothelial function and bone mineral density in very elderly women. *J Gerontol A Biol Sci Med Sci.* 2000 Apr;55(4):B183-90.
- 17.) Itoi H, Minakami H, Sato I. Comparison of the long-term effects of oral estriol with the effects of conjugated estrogen, 1-alpha-hydroxyvitamin D3 and calcium lactate on vertebral bone loss in early menopausal women. *Maturitas.* 1997 Sep;28(1):11-7.
- 18.) Itoi H, Minakami H, Iwasaki R, et al. Comparison of the long-term effects of oral estriol with the effects of conjugated estrogen on serum lipid profile in early menopausal women. *Maturitas.* 2000 Oct 31;36(3):217-22.
- 19.) Raz R, Stamm WE. A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. *N Engl J Med.* 1993 Sep;329(11):753-6.
- 20.) de Lignieres B. Oral micronized progesterone. *Clin Ther.* 1999 Jan;21(1):41-60.
- 21.) Maxson WS, Hargrove JT. Bioavailability of oral micronized progesterone. *Fertil Steril.* 1985 Nov;44(5):622-6.
- 22.) Norman TR, Morse CA, Dennerstein L. Comparative bioavailability of orally and vaginally administered progesterone. *Fertil Steril.* 1991 Dec;56(6):1034-9.

- 23.) Tavaniotou A, Smitz J, Bourgain C, et al. Comparison between different routes of progesterone administration as luteal phase support in infertility treatments. *Hum Reprod Update*. 2000 Mar-Apr;6(2):139-48.
- 24.) Leonetti HB, Longo S, Anasti JN. Transdermal progesterone cream for vasomotor symptoms and postmenopausal bone loss. *Obstet Gynecol*. 1999 Aug;94(2):225-8.
- 25.) Bolaji II, Grimes H, Mortimer G, et al. Low-dose progesterone therapy in oestrogenised postmenopausal women: effects of plasma lipids, lipoproteins and liver function parameters. *Eur J Obstet Gynecol Reprod Biol*. 1993 Jan;48(1):61-8.
- 26.) Darj E, Axelsson O, Carlstrom K, et al. Liver metabolism during treatment with estradiol and natural progesterone. *Gynecol Endocrinol*. 1993 Jun;7(2):111-4.
- 27.) Arafat ES, Hargrove JT, Maxson WS, et al. Sedative and hypnotic effects of oral administration of micronized progesterone may be mediated through its metabolites. *Am J Obstet Gynecol*. 1988 Nov;159(5):1203-9.
- 28.) Glaser RL, Zava DT, Wurtzbacher D. Pilot study: absorption and efficacy of multiple hormones delivered in a single cream applied to the mucous membranes of the labia and vagina. *Gynecol Obstet Invest*. 2008;66(2):111-8.
- 29.) Miller KK. Androgen deficiency in women. *J Clin Endocrinol Metab*. 2001 Jun;86(6):2395-401.
- 30.) Miller K, Corcoran C, Armstrong C, et al. Transdermal testosterone administration in women with acquired immunodeficiency syndrome wasting: a pilot study. *J Clin Endocrinol Metab*. 1998 Aug;83(8):2717-25.
- 31.) Davis SR, Walker KZ, Strauss BJ. Effects of estradiol with and without testosterone on body composition and relationships with lipids in postmenopausal women. *Menopause*. 2000 Nov-Dec;7(6):395-401.
- 32.) Labrie F, Diamond P, Cusan L, et al. Effect of 12 month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women. *J Clin Endocrinol Metab*. 1997 Oct;82(10):3498-505.
- 33.) Legrain S, Massien C, Lahlou N, et al. Dehydroepiandrosterone replacement administration: pharmacokinetic and pharmacodynamic studies in healthy elderly subjects. *J Clin Endocrinol Metab*. 2000 Sep;85(9):3208-17.
- 34.) Barnhart KT, Freeman E, Grisso JA, et al. The effect of dehydroepiandrosterone supplementation to symptomatic perimenopausal women on serum endocrine profiles, lipid parameters, and health-related quality of life. *J Clin Endocrinol Metab*. 1999 Nov;84(11):3896-902.
- 35.) Morales AJ, Haubrich RH, Hwang JY, et al. The effect of six months treatment with a 100 mg daily dose of dehydroepiandrosterone (DHEA) on circulating sex steroids, body composition and muscle strength in age-advanced men and women. *Clin Endocrinol (Oxf)*. 1998 Oct;49(4):421-32.
- 36.) Hargrove JT, Maxson WS, Wentz AC, et al. Menopausal hormone replacement therapy with continuous daily oral micronized estradiol and progesterone. *Obstet Gynecol*. 1989 Apr;73(4):606-12.
- 37.) Shifren JL, Braunstein GD, Simon JA, et al. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. *N Engl J Med*. 2000 Sep 7;343(10):682-8.
- 38.) Nahoul K, Dehennin L, Jondet M, et al. Profiles of plasma estrogens, progesterone and their metabolites after oral or vaginal administration of estradiol or progesterone. *Maturitas*. 1993 May;16(3):185-202.
- 39.) Lee JR. *What Your Doctor May Not Tell You About Menopause*. New York, NY: Warner Books; 1996:267.
- 40.) Gillson G, Marsden T. *You've Hit Menopause: Now What? 3 Simple Steps to Restoring Hormone Balance*. Calgary, Alberta, Canada: Blitzprint;2003:110-3.
- 41.) Hertoghe T. *The Hormone Handbook*. Surrey, United Kingdom: International Medical Publications; 2006:134, 175-6, 204.
- 42.) Stephenson K. *Awakening Athens*. Tyler, TX: Health, Heart & Mind Institute; 2004:229, 242, 249, 268, 299, 306, 335.
- 43.) Taylor EB, Bell-Taylor A. *Are Your Hormones Making You Sick*. United States of America: Physicians Natural Medicine Inc.;2000:174, 182.
- 44.) Northrup C. *The Wisdom of Menopause*. New York, NY: Bantam Book; 2001:127, 162.